Press Releases | PTC Therapeutics, Inc.

The press releases contained in this archive section are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. PTC Therapeutics disavows any obligation to update the information contained in such press releases after the date of their issuance.

Year

Sep 18, 2019

PTC Therapeutics Announces Pricing of Private Offering of Convertible Senior Notes

SOUTH PLAINFIELD, N.J. , Sept. 18, 2019 /PRNewswire/ -- PTC Therapeutics, Inc. (Nasdaq: PTCT) announced today that it has priced its private offering of $250.0 million aggregate principal amount of its convertible senior notes due 2026 (the "Notes"). The Notes will be sold only to qualified

Sep 18, 2019

PTC Therapeutics Announces Pricing of Public Offering of Common Stock

SOUTH PLAINFIELD, N.J. , Sept. 18, 2019 /PRNewswire/ -- PTC Therapeutics, Inc. (Nasdaq: PTCT) announced today the pricing of a public offering of 2,475,248 shares of its common stock at a public offering price of $40.40 per share, before underwriting discounts and commissions.

Sep 17, 2019

PTC Therapeutics Announces Proposed Private Offering of Convertible Senior Notes

SOUTH PLAINFIELD, N.J. , Sept. 17, 2019 /PRNewswire/ -- PTC Therapeutics, Inc. (Nasdaq: PTCT) announced today that it is commencing an offering of $250.0 million aggregate principal amount of its convertible senior notes due 2026 (the "Notes"), subject to market conditions and other factors.

Sep 17, 2019

PTC Therapeutics Announces Proposed Public Offering of Common Stock

SOUTH PLAINFIELD, N.J. , Sept. 17, 2019 /PRNewswire/ -- PTC Therapeutics, Inc. (Nasdaq: PTCT) announced today that it is commencing a public offering of $100.0 million of shares of its common stock. PTC intends to grant the underwriter an option for a period of 30 days to purchase up to an

Sep 06, 2019

PTC Therapeutics Celebrates the Fifth Anniversary of STRIVE Grant Awards by Announcing 2019 Award Winners

-Global program recognizes excellence and innovation in the Duchenne muscular dystrophy community- -28 projects awarded funding since its inception- SOUTH PLAINFIELD, N.J. , Sept. 6, 2019 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) is pleased to announce the recipients of the Company's

Aug 06, 2019

PTC Therapeutics Reports Second Quarter 2019 Financial Results and Provides a Corporate Update

-Translarna™ approved in Brazil & PTC entered first annual contract with Ministry of Health- -Emflaza® receives FDA approval for a label expansion to treat DMD patients 2-5 years of age- -PTC expands gene therapy infrastructure & portfolio- SOUTH PLAINFIELD, N.J. , Aug.

Aug 05, 2019

PTC Therapeutics Expands Presence in New Jersey by Securing State-of-the-Art Biologics Facility

- Facility will support gene therapy production and continued development of pipeline of investigational medicines - - PTC to gain access to highly-qualified specialists in biologics operations - SOUTH PLAINFIELD, N.J. , Aug. 5, 2019 /PRNewswire/ -- PTC Therapeutics, Inc.

Jul 31, 2019

PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SOUTH PLAINFIELD, N.J. , July 31, 2019 /PRNewswire/ -- PTC Therapeutics , Inc. (NASDAQ: PTCT) today announced that on July 26, 2019 it approved non-statutory stock options to purchase an aggregate of 208,100 shares of its common stock to 72 new employees.

Jul 23, 2019

PTC Therapeutics to Host Conference Call to Discuss Second Quarter 2019 Financial Results

SOUTH PLAINFIELD, N.J. , July 23, 2019 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the Company will host a webcast conference call to report its second quarter 2019 financial results and provide an update on the company's business and outlook on Tuesday, August 6,

Jul 01, 2019

PTC Therapeutics Announces Strategic Gene Therapy Licensing Agreement with Odylia Therapeutics

- Collaboration expands PTC's Gene Therapy portfolio to rare ophthalmic diseases - SOUTH PLAINFIELD, N.J. and BOSTON , July 1, 2019 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) and Odylia Therapeutics today announced a strategic collaboration to develop novel gene therapies in rare

Pagination

First page
Previous page
…
Page 21
Page 22
Current page 23
Page 24
Page 25
…
Next page
Last page